We are live on ! Find out more
TRCT

Tower Research Capital (TRC) Portfolio holdings

AUM $4.08B
1-Year Est. Return 58.77%
This Fund
S&P 500
This Quarter Est. Return
+19.09%
1 Year Est. Return
+58.77%
3 Year Est. Return
+143.94%
5 Year Est. Return
+167.17%
10 Year Est. Return
+536.06%
AUM
$3.27B
AUM Growth
-$5.76B
Cap. Flow
-$1.51B
Cap. Flow %
-46.09%
Top 10 Hldgs %
34.23%
Holding
5,681
New
749
Increased
1,274
Reduced
3,081
Closed
446

Sector Composition

Rank Sector Weight
1 Technology 9.66%
2 Financials 8.46%
3 Healthcare 8.24%
4 Consumer Discretionary 7.74%
5 Industrials 6.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
VERI icon
3701
Veritone
VERI
$139M
$26K ﹤0.01%
900
-20,768
-96% -$359K
XCUR icon
3702
Exicure
XCUR
$8.35M
$26K ﹤0.01%
100
-281
-74% -$70.3K
XTNT icon
3703
Xtant Medical Holdings
XTNT
$43.8M
$26K ﹤0.01%
21,607
+8,401
+64% +$10.8K
TECX
3704
Tectonic Therapeutic
TECX
$664M
$26K ﹤0.01%
157
-15
-9% -$2.67K
RADA
3705
DELISTED
Rada Electronic Industries Ltd
RADA
$26K ﹤0.01%
2,702
+1,938
+254% +$14.9K
AERI
3706
DELISTED
Aerie Pharmaceuticals
AERI
$26K ﹤0.01%
1,879
-2,089
-53% -$25.2K
CSLT
3707
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
$26K ﹤0.01%
+19,676
New +$22.1K
DVD
3708
DELISTED
Dover Motorsports
DVD
$26K ﹤0.01%
11,425
-19,522
-63% -$33.9K
DSPG
3709
DELISTED
DSP Group Inc
DSPG
$26K ﹤0.01%
1,588
-18,484
-92% -$284K
FPRX
3710
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$26K ﹤0.01%
1,538
-32,907
-96% -$412K
INBX
3711
DELISTED
Inhibrx, Inc. Common Stock
INBX
$26K ﹤0.01%
+774
New +$20.6K
APOG icon
3712
Apogee Enterprises
APOG
$888M
$25K ﹤0.01%
771
-23,503
-97% -$636K
ATOM icon
3713
Atomera
ATOM
$212M
$25K ﹤0.01%
1,504
-12,421
-89% -$130K
AWRE icon
3714
Aware
AWRE
$26.4M
$25K ﹤0.01%
7,189
-5,993
-45% -$17.8K
BOIL icon
3715
ProShares Ultra Bloomberg Natural Gas
BOIL
$402M
$25K ﹤0.01%
6
-2
-25% -$12.4K
BSV icon
3716
Vanguard Short-Term Bond ETF
BSV
$45.7B
$25K ﹤0.01%
302
+300
+15,000% +$24.9K
CCLD icon
3717
CareCloud
CCLD
$104M
$25K ﹤0.01%
2,771
+1,011
+57% +$9.32K
CTMX icon
3718
CytomX Therapeutics
CTMX
$730M
$25K ﹤0.01%
3,824
-34,590
-90% -$247K
GNPX icon
3719
Genprex
GNPX
$2.46M
-1
Closed -$155K
IMNN icon
3720
Imunon
IMNN
$6.64M
$25K ﹤0.01%
179
+102
+132% +$12.2K
INOD icon
3721
Innodata
INOD
$2.03B
$25K ﹤0.01%
4,674
+4,035
+631% +$16K
ITOS
3722
DELISTED
iTeos Therapeutics
ITOS
$25K ﹤0.01%
745
-1,234
-62% -$32.7K
MX icon
3723
Magnachip Semiconductor
MX
$137M
$25K ﹤0.01%
1,878
+905
+93% +$12.5K
NKTX icon
3724
Nkarta
NKTX
$165M
$25K ﹤0.01%
408
-2,189
-84% -$90.9K
OSUR icon
3725
OraSure Technologies
OSUR
$277M
$25K ﹤0.01%
2,398
-62,182
-96% -$816K

Similar funds

Tower Research Capital (TRC)'s Q4 2020 Portfolio in Review

As of Q4 2020, Tower Research Capital (TRC) held 5,681 positions worth $3.27B, down 64% from $9.03B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Tower Research Capital (TRC) withdrew a net $1.51B in Q4 2020, closing 446 positions and reducing 3,081 holdings. Its most notable exit was iShares Russell 2000 Growth ETF, an estimated $13.7M position sold in full.

By sector, the portfolio is most concentrated in Technology at 9.7% of assets, up from 6.3% a quarter earlier, followed by Financials and Healthcare.

Against the trend, Tower Research Capital (TRC) opened a new position in iShares Russell 1000 ETF worth $24.4M.

  • Tower Research Capital (TRC)'s largest Q4 2020 buy was iShares Russell 1000 ETF: 115,321 shares worth $24.4M.
  • Tower Research Capital (TRC) added most to State Street SPDR S&P 500 ETF Trust in Q4 2020, an estimated $99.8M increase.
  • Tower Research Capital (TRC)'s biggest Q4 2020 reduction was iShares Russell 2000 ETF, cutting an estimated $36.3M.
  • Tower Research Capital (TRC) fully exited iShares Russell 2000 Growth ETF in Q4 2020, selling an estimated $13.7M.
  • Tower Research Capital (TRC)'s ten largest holdings make up 34% of its $3.27B portfolio in Q4 2020.
  • Tower Research Capital (TRC) opened 749 new positions and closed 446 in Q4 2020.
  • Tower Research Capital (TRC)'s portfolio value fell 64% quarter-over-quarter to $3.27B.

Based on Tower Research Capital (TRC)'s 13F filing for Q4 2020, filed 16 Feb 2021.